MarketCap
Facebook
X
TelegramAnnual report 2022
added 03-30-2023
HTG Molecular Diagnostics Accounts Receivables 2011-2026 | HTGM
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables HTG Molecular Diagnostics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.42 M | 2.09 M | 1.59 M | 3.16 M | 5.01 M | 6.36 M | 1.38 M | 716 K | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 6.36 M | 716 K | 2.72 M |
Quarterly Accounts Receivables HTG Molecular Diagnostics
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 960 K | 1.26 M | 749 K | 2.09 M | 1.9 M | 1.42 M | 1.25 M | 1.59 M | 1.59 M | 1.59 M | 1.59 M | 3.16 M | 3.16 M | 3.16 M | 3.16 M | 5.01 M | 5.01 M | 5.01 M | 5.01 M | 6.36 M | 6.36 M | 6.36 M | 6.36 M | 1.38 M | 1.38 M | 1.38 M | 1.38 M | 716 K | 716 K | 716 K | 716 K | 801 K | 801 K | 801 K | 801 K | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 6.36 M | 716 K | 2.45 M |
Accounts Receivables of other stocks in the Diagnostics research industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
114 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Accelerate Diagnostics
AXDX
|
2.42 M | - | -61.36 % | $ 2.46 M |  USA |
 |
Burning Rock Biotech Limited
BNR
|
88.2 M | $ 20.15 | -2.3 % | $ 217 M |  China |
 |
Co-Diagnostics
CODX
|
304 K | $ 0.17 | -6.7 % | $ 4.99 M | USA |
 |
Biocept
BIOC
|
2.15 M | - | -13.05 % | $ 7.29 M | USA |
 |
Danaher Corporation
DHR
|
3.54 B | $ 228.92 | -0.76 % | $ 167 B | USA |
 |
Chembio Diagnostics
CEMI
|
6.54 M | - | 0.22 % | $ 16.8 M | USA |
 |
DexCom
DXCM
|
974 M | $ 66.37 | -1.03 % | $ 25.6 B | USA |
 |
BioNano Genomics
BNGO
|
4.75 M | $ 1.53 | 2.0 % | $ 1.94 M | USA |
 |
Castle Biosciences
CSTL
|
51.2 M | $ 38.9 | -1.04 % | $ 1.08 B | USA |
 |
DermTech
DMTK
|
2.58 M | - | -11.32 % | $ 2.94 M | USA |
 |
DarioHealth Corp.
DRIO
|
3.16 M | $ 11.38 | 6.36 % | $ 323 M |  Israel |
 |
IQVIA Holdings
IQV
|
3.2 B | $ 225.41 | -1.0 % | $ 40.9 B | USA |
 |
Enzo Biochem
ENZ
|
3.99 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
249 M | $ 101.56 | -0.33 % | $ 18.8 B | USA |
 |
Fulgent Genetics
FLGT
|
69 M | $ 26.27 | -0.83 % | $ 794 M | USA |
 |
Global Cord Blood Corporation
CO
|
416 M | - | - | $ 399 M | China |
 |
CareDx, Inc
CDNA
|
51.1 M | $ 18.84 | -1.21 % | $ 1.01 B | USA |
 |
Myriad Genetics
MYGN
|
121 M | $ 6.15 | -0.32 % | $ 557 M | USA |
 |
NeoGenomics
NEO
|
151 M | $ 11.76 | -3.84 % | $ 1.49 B | USA |
 |
National Research Corporation
NRC
|
12.4 M | $ 18.77 | 0.64 % | $ 461 M | USA |
 |
Anixa Biosciences
ANIX
|
173 K | $ 3.12 | - | $ 99.5 K | USA |
 |
Precipio
PRPO
|
1.3 M | $ 22.98 | -1.84 % | $ 29.8 M | USA |
 |
Personalis
PSNL
|
8.14 M | $ 7.96 | -0.13 % | $ 472 M | USA |
 |
Heska Corporation
HSKA
|
29.5 M | - | - | $ 1.31 B | USA |
 |
QIAGEN N.V.
QGEN
|
381 M | $ 44.97 | -0.77 % | $ 10 B |  Niderland |
 |
Guardant Health
GH
|
110 M | $ 102.14 | 1.53 % | $ 12.5 B | USA |
 |
RadNet
RDNT
|
186 M | $ 71.35 | -0.2 % | $ 5.21 B | USA |
 |
Aspira Women's Health
AWH
|
1.24 M | - | -6.19 % | $ 10.5 M | USA |
 |
Soleno Therapeutics
SLNO
|
133 K | $ 46.3 | 0.02 % | $ 1.86 B | USA |
 |
ENDRA Life Sciences
NDRA
|
6.85 K | $ 4.53 | -4.83 % | $ 2.43 M | USA |
 |
Illumina
ILMN
|
735 M | $ 131.16 | -1.2 % | $ 20.9 B | USA |
 |
Charles River Laboratories International
CRL
|
721 M | $ 199.48 | -1.24 % | $ 10.2 B | USA |
 |
Thermo Fisher Scientific
TMO
|
8.19 B | $ 579.45 | -0.69 % | $ 221 B | USA |
 |
Twist Bioscience Corporation
TWST
|
57 M | $ 31.72 | -1.34 % | $ 1.9 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.3 B | $ 173.53 | -1.12 % | $ 19.3 B | USA |
|
Biodesix
BDSX
|
8.6 M | $ 6.8 | 1.19 % | $ 882 M | USA |
 |
Motus GI Holdings
MOTS
|
76 K | - | -34.28 % | $ 263 K | Israel |